2019; 68: 167-71.4）Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet 2023; 401: 858-73.1）Wenzel SE. Severe adult asthmas: Integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med 2021; 203: 809-21.2）Nagase H. Severe asthma in Japan. Allergol Int 3）Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med 2022; 386: 157-71.5）Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-66.6）Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486-96.7）Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475-85.デュピルマブの治療有効性に関わるマイクロRNAの同定文 献8）Busse WW, Paggiaro P, Muñoz X, Casale TB, Castro M, Canonica GW, et al. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J 2021; 58: 2004605.9）Weidner J, Bartel S, Kılıç A, Zissler UM, Renz H, Schwarze J, et al. Spotlight on microRNAs in allergy and asthma. Allergy 2020; 76: 1661-78.10）Hirai K, Shirai T, Shimoshikiryo T, Ueda M, Gon Y, Maruoka S, et al. Circulating microRNA‐15b‐5p as a biomarker for asthma‐COPD overlap. Allergy 2021; 76: 766-74.11）Hirai K, Uehara S, Shirai T, Rachi Y, Kimura T, Akamatsu T, et al. Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma. Allergy 2021; 76: 2589-92.19
元のページ ../index.html#33